289 related articles for article (PubMed ID: 27120806)
1. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
Luszczak S; Simpson BS; Stopka-Farooqui U; Sathyadevan VK; Echeverria LMC; Kumar C; Costa H; Haider A; Freeman A; Jameson C; Ratynska M; Ben-Salha I; Sridhar A; Shaw G; Kelly JD; Pye H; Gately KA; Whitaker HC; Heavey S
Sci Rep; 2020 Sep; 10(1):14380. PubMed ID: 32873828
[TBL] [Abstract][Full Text] [Related]
3. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
5. Combined PI3Kα-mTOR Targeting of Glioma Stem Cells.
Eckerdt FD; Bell JB; Gonzalez C; Oh MS; Perez RE; Mazewski C; Fischietti M; Goldman S; Nakano I; Platanias LC
Sci Rep; 2020 Dec; 10(1):21873. PubMed ID: 33318517
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
[TBL] [Abstract][Full Text] [Related]
7. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase.
Colamonici M; Blyth G; Saleiro D; Szilard A; Bliss-Moreau M; Giles FJ; Altman JK; Beauchamp EM; Platanias LC
Oncotarget; 2015 Apr; 6(10):8062-70. PubMed ID: 25823922
[TBL] [Abstract][Full Text] [Related]
9. PIM kinases as therapeutic targets against advanced melanoma.
Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
[TBL] [Abstract][Full Text] [Related]
10. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
[TBL] [Abstract][Full Text] [Related]
11. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.
Curi DA; Beauchamp EM; Blyth GT; Arslan AD; Donato NJ; Giles FJ; Altman JK; Platanias LC
Oncotarget; 2015 Oct; 6(32):33206-16. PubMed ID: 26375673
[TBL] [Abstract][Full Text] [Related]
13. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
Yadav AK; Kumar V; Bailey DB; Jang BC
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
[TBL] [Abstract][Full Text] [Related]
14. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
[TBL] [Abstract][Full Text] [Related]
15. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
Chen LS; Yang JY; Liang H; Cortes JE; Gandhi V
Leuk Lymphoma; 2016 Dec; 57(12):2863-2873. PubMed ID: 27054578
[TBL] [Abstract][Full Text] [Related]
16. Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models.
Jones NM; Rowe MR; Shepherd PR; McConnell MJ
Int J Oncol; 2016 Jul; 49(1):207-16. PubMed ID: 27176780
[TBL] [Abstract][Full Text] [Related]
17. PIM kinases facilitate lentiviral evasion from SAMHD1 restriction via Vpx phosphorylation.
Miyakawa K; Matsunaga S; Yokoyama M; Nomaguchi M; Kimura Y; Nishi M; Kimura H; Sato H; Hirano H; Tamura T; Akari H; Miura T; Adachi A; Sawasaki T; Yamamoto N; Ryo A
Nat Commun; 2019 Apr; 10(1):1844. PubMed ID: 31015445
[TBL] [Abstract][Full Text] [Related]
18. Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Chen X; Cao Y; Sedhom W; Lu L; Liu Y; Wang H; Oka M; Bornstein S; Said S; Song J; Lu SL
Mol Oncol; 2020 Jan; 14(1):139-158. PubMed ID: 31600013
[TBL] [Abstract][Full Text] [Related]
19. RNA-Seq analysis reveals that spring viraemia of carp virus induces a broad spectrum of PIM kinases in zebrafish kidney that promote viral entry.
Pereiro P; Álvarez-Rodríguez M; Valenzuela-Muñoz V; Gallardo-Escárate C; Figueras A; Novoa B
Fish Shellfish Immunol; 2020 Apr; 99():86-98. PubMed ID: 32004617
[TBL] [Abstract][Full Text] [Related]
20. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
